Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site

Share

The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.  

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG

Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024.  No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States.

Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's downtown facility. Biomay's headquarters site is a recently constructed, state-of-the-art biomanufacturing facility.

Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay's business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company's scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.

Contact:
Dr. Angela Neubauer, SVP Client Business; E-Mail: request@biomay.com / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria www.biomay.com

Images

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

McFIT “The Original” Launches International Franchising – One of Europe’s Most Recognized Fitness Brands Enters a New Era22.1.2026 12:00:00 CET | Press release

McFIT, a cornerstone of the European fitness landscape since 1997, is entering a new chapter in its corporate development: for the first time, the successful gym concept will be offered as an international franchise. This move paves the way for McFIT’s global franchise growth in previously untapped markets without company-owned locations.

How the CO2 price will affect heating costs in Europe22.1.2026 08:00:00 CET | Press release

The EU-wide uniform CO2 price for the building and transport sectors planned from 2028 will change the heating costs of 100 million households. A study by the Bertelsmann Stiftung shows that in many countries, including Germany, the additional burdens are likely to be limited. In Scandinavia, households could even see some relief. But in some Central and Eastern European regions, heating costs would go up noticeably. The study also shows that if the money from CO2 pricing is used the right way, it is enough to ease the burden households facing the greatest burden.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye